Effectiveness of itraconazole in the prophylaxis of fungal infections in AIDS patiens：a meta-analysis of randomized controlled trials

Abstract

Abstract: Objective To evaluate the effectiveness of itraconazole in the prophylaxis of fungal infections in AIDS patiens.Methods A computerized literature searching had been carried out in Cochrane Database of Clinical Controlled Trials, PubMed, EMbase, EBSCO, Wanfang and Tsinghua Tongfang database, from January 1981 to July 2013. All randomized controlled trial (RCT) papers about prophylactic use of itraconazole to prevent fungal infections in AIDS patiens were enrolled. Meta-analysis was conducted using Stata 10.0 to calculate the pooled RR value (95%CI). Consistency test was performed.Results Finally 3 pieces of RCT papers were enrolled. It showed that prophylactic use of itraconazole can significantly reduce the rate of fungal infections in AIDS patients, with the pooled relative risk (RR) and 95% confidence interval (CI) was 0.54 (95%CI:0.44~0.67),P<0.05. However it showed no statistically significant differences in the rate of invasive fungal infections, with the pooled relative risk (RR) and 95% confidence interval (CI) was 0.38 (95%CI:0.13~1.10),P >0.05. There was no statistically significant differences in case fatality rate, with the pooled relative risk (RR) and 95% confidence interval (CI) was 1.14 (95%CI:0.79~1.65),P >0.05.Conclusion Prophylactic use of itraconazole in AIDS patients can significantly reduce the overall rate of fungal infections, but for invasive fungal infections has not been shown. Whether AIDS patients should use itraconazole to prevent fungal infections, it needs to be assessed carefully, and generate different prevention strategies according to the rates of different disease stages.

Key words: itraconazole, Acquired Immune Deficiency Syndrome, fungal infections, Meta-analysis

CLC Number:

R379
R512.91

YANG Xiao-yi, JIANG Jun-jun, YE Li, HUANG Jie-gang, ZHOU Bo, LIANG Bing-yu, TAO Ren-chuan, CAO Cun-wei, SHAO Yi-ming, LIANG Hao. Effectiveness of itraconazole in the prophylaxis of fungal infections in AIDS patiens：a meta-analysis of randomized controlled trials[J]. Chinese Journal of Mycology, 2013, 8(6): 352-357.

References

[1] 李若瑜.医学真菌学现状与未来[C].中国菌物学会第四届会员代表大会暨全国第七届菌物学学术讨论会论文集, 2008:18.
[2] 杨仕宏, 薛增凤, 季福玲.艾滋病与深部真菌感染的现状及治疗[J].现代医药卫生, 2007, 23(17):2597-2598.
[3] 程波, 黄子斌, 裴智.口腔真菌感染为首发症状的艾滋病1例[J].中国皮肤性病学杂志, 2013, 27(1):95.
[4] 王艳芳.以霉菌性食管炎为首发症状的艾滋病临床分析[J].现代消化及介入诊疗, 2010, 15(6):377-378.
[5] 黄增海.以血液系统表现为首发症状的爱滋病临床探讨[J].中外健康文摘, 2013(15):11-12.
[6] Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America[J]. MMWR Recomm Rep, 2009, 58(RR-4):1-207.
[7] Bicanict, Harrisonts. Cryptococcal meningitis[J]. BR MED Bull, 2005, 72(1): 99-118.
[8] Mckinsey DS, Wheat LJ, Cloud GA, et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group[J]. Clinical Infectious Diseases: an Official Publica, 1999, 28(5): 1049-1056.
[9] Chaiwarith R, Fakthongyoo A, Praparattanapan J, et al. Itraconazole vs fluconazole as a primary prophylaxis for fungal infections in HIV-infected patients in Thailand[J]. Current HIV Research, 2011, 9(5): 334-338.
[10] Chariyalertsak S, Supparatpinyo K, Sirisanthana T, et al. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand[J]. Clinical Infectious Diseases:an Official Publica, 2002, 34(2): 277-284.
[11] Smith DE, Bell J, Johnson M, et al. A randomized, double-blind, placebo-controlled study of itraconazole capsules for the prevention of deep fungal infections in immunodeficient patients with HIV infection[J]. HIV Medicine, 2001, 2(2): 78-83.
[12] 麦劲壮, 李河, 方积乾, 等.Meta分析中失安全系数的估计[J].循证医学, 2006(5):297-300.
[13] Shen YZ, Qi TK, Ma JX, et al. Invasive fungal infections among inpatients with acquired immune deficiency syndrome at a Chinese university hospital[J]. Mycoses, 2007, 50(6): 475-480.
[14] 段勇波, 杨皓莹.HIV/AIDS患者机会感染特点及与CD_4的关系探讨[J].吉林医学, 2011(27):5679.
[15] 赵文化, 尹光芝.艾滋病口腔白色念珠菌感染75例临床观察[J].西南军医, 2009, 11(5):868-869.
[16] 张路坤, 曹廷智, 孙丽琴, 等.深圳地区500例HIV/AIDS患者口腔真菌定植状况及药敏研究[J].中华实验和临床感染病杂志(电子版), 2013(1):100-103.
[17] Lestner J, Hope WW. Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections[J]. Expert Opinion on Drug Metabolism & Toxicology, 2013, 9(7): 911-926.